Go Pro

Jade Biosciences (JBIO) 10K Form and Latest SEC Filings 2026

Jade Biosciences logo
$21.07 +1.92 (+10.02%)
As of 10:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Jade Biosciences SEC Filings & Recent Activity

Jade Biosciences (NASDAQ:JBIO) has submitted 362+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Jade Biosciences's financial statements. The most recent filing was a Form SCHEDULE 13G submitted on July 17, 2026.

Form 4
Jade Biosciences, Inc. Reports Ownership Change on Jun. 26, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Jade Biosciences Files Current Report on Jul. 1, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Jade Biosciences Files Annual Report on Mar. 6, 2026

The 10-K contains Jade Biosciences's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Jade Biosciences SEC Filing History

Browse Jade Biosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
07/17/2026 3:05 PM
Jade Biosciences (1798749) Subject
Paradigm Biocapital Advisors LP (1855655) Filed by
Form SCHEDULE 13G
07/08/2026 4:43 PM
Jade Biosciences (1798749) Subject
Janus Henderson Group Ltd. (1274173) Filed by
Form SCHEDULE 13G/A
07/01/2026 3:41 PM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/26/2026 8:11 PM
Eisner Mark (1834161) Reporting
Jade Biosciences (1798749) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/26/2026 8:20 PM
Eisner Mark (1834161) Reporting
Jade Biosciences (1798749) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2026 6:15 AM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2026 3:41 PM
Jade Biosciences (1798749) Issuer
Klein Lawrence Otto (1762583) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:42 PM
DOBMEIER ERIC (1202785) Reporting
Jade Biosciences (1798749) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:47 PM
CAIN CHRISTOPHER W. (1817733) Reporting
Jade Biosciences (1798749) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:37 PM
Fairmount Funds Management LLC (1802528) Reporting
Fairmount Healthcare Co-Invest IV L.P. (2042283) Reporting
Fairmount Healthcare Fund II L.P. (1769651) Reporting
Harwin Peter Evan (1663607) Reporting
Jade Biosciences (1798749) Issuer
Kiselak Tomas (1830177) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:37 PM
Jade Biosciences (1798749) Issuer
Lavelle Erin (1737613) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2026 4:30 PM
Fairmount Funds Management LLC (1802528) Filed by
Jade Biosciences (1798749) Subject
Form SCHEDULE 13D/A
06/04/2026 4:07 PM
Jade Biosciences (1798749) Filer
Form 424B5
06/04/2026 4:09 PM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/01/2026 6:55 AM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/17/2026 11:15 PM
Jade Biosciences (1798749) Filer
Form EFFECT
05/17/2026 11:15 PM
Jade Biosciences (1798749) Filer
Form EFFECT
05/15/2026 3:44 PM
Jade Biosciences (1798749) Filer
Form 424B3
05/15/2026 11:38 AM
Jade Biosciences (1798749) Subject
JANUS HENDERSON GROUP PLC (1274173) Filed by
Form SCHEDULE 13G/A
05/07/2026 4:26 PM
Jade Biosciences (1798749) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/07/2026 4:15 PM
Jade Biosciences (1798749) Filer
Form S-3
Registration statement under Securities Act of 1933  
05/07/2026 4:20 PM
Jade Biosciences (1798749) Filer
Form S-3
Registration statement under Securities Act of 1933  
05/07/2026 3:33 PM
Jade Biosciences (1798749) Filer
Form 424B3
05/07/2026 3:35 PM
Jade Biosciences (1798749) Filer
Form 424B3
04/28/2026 3:15 PM
Jade Biosciences (1798749) Filer
Form ARS
04/27/2026 3:12 PM
BlackRock, Inc. (2012383) Filed by
Jade Biosciences (1798749) Subject
Form SCHEDULE 13G/A
04/22/2026 6:18 AM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2026 3:18 PM
Jade Biosciences (1798749) Filer
Form PRE 14A
04/02/2026 3:10 PM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2026 3:49 PM
Jade Biosciences (1798749) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/06/2026 3:34 PM
Jade Biosciences (1798749) Filer
Form POS EX
03/06/2026 3:36 PM
Jade Biosciences (1798749) Filer
Form POS EX
03/06/2026 3:26 PM
Jade Biosciences (1798749) Filer
Form 424B3
03/06/2026 3:27 PM
Jade Biosciences (1798749) Filer
Form 424B3
03/06/2026 3:15 PM
Jade Biosciences (1798749) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/06/2026 6:11 AM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2026 5:04 AM
Jade Biosciences (1798749) Subject
Sofinnova Venture Partners X, L.P. (1680200) Filed by
Form SCHEDULE 13D/A
02/17/2026 5:11 PM
Jade Biosciences (1798749) Subject
Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by
Form SCHEDULE 13G/A
02/13/2026 7:00 PM
Jade Biosciences (1798749) Issuer
King Andrew James (1823187) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 7:00 PM
Frohlich Tom (1823925) Reporting
Jade Biosciences (1798749) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 7:00 PM
Balta Elizabeth (1884087) Reporting
Jade Biosciences (1798749) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
7 Bankers Met in Secret (Now We Pay for It) (Ad)

A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in secret, used fake names, and told absolutely no one where they were going. On November 22nd, 1910, seven of America's most powerful bankers gathered on Jekyll Island to design the Federal Reserve. Their goal? To create a system where they control the money supply and you foot the bill. That system has created $38 trillion in debt, destroyed 98% of the dollar's purchasing power, and now they're preparing the final move: Central bank digital currencies (CBDCs). But if you have at least $100,000 saved and you're concerned about what's coming, you need to hear this.tc pixel

Watch now before this presentation is taken down.
02/13/2026 7:00 PM
Dahms Bradford D. (1787307) Reporting
Jade Biosciences (1798749) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 7:48 AM
Deep Track Capital, LP (1856083) Filed by
Jade Biosciences (1798749) Subject
Form SCHEDULE 13G/A
01/05/2026 6:17 AM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2025 11:15 PM
Jade Biosciences (1798749) Filer
Form EFFECT
12/22/2025 3:38 PM
Jade Biosciences (1798749) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/21/2025 11:15 PM
Jade Biosciences (1798749) Filer
Form EFFECT
12/19/2025 3:28 PM
Jade Biosciences (1798749) Filer
Form 424B3
12/15/2025 6:11 AM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 7:18 AM
Deep Track Capital, LP (1856083) Filed by
Jade Biosciences (1798749) Subject
Form SCHEDULE 13G/A
11/14/2025 6:00 AM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 6:13 AM
Jade Biosciences (1798749) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/17/2025 5:40 PM
BlackRock, Inc. (2012383) Filed by
Jade Biosciences (1798749) Subject
Form SCHEDULE 13G/A
10/16/2025 6:35 PM
Jade Biosciences (1798749) Subject
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Form SCHEDULE 13G
10/08/2025 3:15 PM
Fairmount Funds Management LLC (1802528) Reporting
Fairmount Healthcare Co-Invest IV L.P. (2042283) Reporting
Fairmount Healthcare Fund II L.P. (1769651) Reporting
Harwin Peter Evan (1663607) Reporting
Jade Biosciences (1798749) Issuer
Kiselak Tomas (1830177) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2025 3:15 PM
Fairmount Funds Management LLC (1802528) Filed by
Jade Biosciences (1798749) Subject
Form SCHEDULE 13D/A
10/07/2025 6:13 AM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/09/2025 6:13 AM
Jade Biosciences (1798749) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2025 3:26 PM
Jade Biosciences (1798749) Filer
Form 8-A12B/A
(Data available from 1/1/2016 forward)

Jade Biosciences SEC Filings - Frequently Asked Questions

Jade Biosciences (JBIO) has submitted 362+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

Jade Biosciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Jade Biosciences's financial statements page.

The most recent filing was a Form SCHEDULE 13G submitted on July 17, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:JBIO) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners